Loading...
Scancell Holdings plc
SCNLF•PNK
Healthcare
Biotechnology
$0.14
$0.00(0.00%)

Over the past four quarters, Scancell Holdings plc demonstrated steady revenue growth, increasing from $2.64M in Q1 2023 to $5.27M in Q4 2023. Operating income reached -$4.67M in Q4 2023, maintaining a consistent -89% margin over recent quarters. Despite fluctuations in R&D and SG&A expenses, EBITDA remained robust at -$4.23M, reflecting operational efficiency. Net income dropped to -$8.77M, with EPS at -$0.01. Disciplined expense management helped sustain profitability, highlighting solid overall financial performance.
Unlock 25+ Years of Financial Data
Get access to extended historical data, advanced metrics, and more with our premium plan